

# Mark C Genovese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/140798/publications.pdf>

Version: 2024-02-01

167  
papers

19,019  
citations

22153  
59  
h-index

11607  
135  
g-index

169  
all docs

169  
docs citations

169  
times ranked

13019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. <i>Modern Rheumatology</i> , 2023, 33, 64-72.	1.8	2
2	Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 469-479.	0.9	30
3	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 184-192.	0.9	40
4	The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States. <i>ACR Open Rheumatology</i> , 2022, 4, 473-482.	2.1	4
5	Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study. <i>Journal of Rheumatology</i> , 2021, 48, 969-976.	2.0	12
6	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. <i>Journal of Rheumatology</i> , 2021, 48, 1230-1238.	2.0	29
7	Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2021, 3, e262-e269.	3.9	28
8	P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial. <i>Rheumatology</i> , 2021, 60, .	1.9	0
9	Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. <i>Rheumatology</i> , 2021, 60, 4991-5001.	1.9	11
10	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	3.4	466
11	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	5.6	339
12	Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. , 2021, 8, 120-129.		5
13	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021, 16, e0244187.	2.5	16
14	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.9	123
15	Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. <i>Journal of Rheumatology</i> , 2020, 47, 924-927.	2.0	34
16	Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years follow-up. <i>Rheumatology</i> , 2020, 59, 292-302.	1.9	43
17	Unique Sjögren's syndrome patient subsets defined by molecular features. <i>Rheumatology</i> , 2020, 59, 860-868.	1.9	41
18	TNF-alpha inhibition for the treatment of cardiac sarcoidosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 546-552.	3.4	27

#	ARTICLE	IF	CITATIONS
19	P225â€fInhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patients with RA: one-year outcomes from the select Phase 3 programme. Rheumatology, 2020, 59, .	1.9	0
20	P235â€fGlucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study. Rheumatology, 2020, 59, .	1.9	1
21	Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatology, The, 2020, 2, e527-e538.	3.9	59
22	O09â€fPooled safety analyses from Phase 3 studies of filgotinib in patients with RA. Rheumatology, 2020, 59, .	1.9	0
23	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1290-1297.	0.9	61
24	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 188.	3.5	2
25	Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2020, 23, 1514-1525.	1.9	8
26	Interleukin-6 receptor blockade or TNFÎ± inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research and Therapy, 2020, 22, 206.	3.5	20
27	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatology, The, 2020, 2, e347-e357.	3.9	51
28	Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD Open, 2020, 6, e000987.	3.8	17
29	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open, 2020, 6, e001095.	3.8	48
30	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Research and Therapy, 2020, 22, 139.	3.5	21
31	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open, 2020, 6, e001096.	3.8	3
32	Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 60.	3.5	14
33	The road to rheumatoid arthritis prevention: challenges and opportunities. Clinical Rheumatology, 2020, 39, 1379-1381.	2.2	6
34	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Research and Therapy, 2020, 22, 14.	3.5	27
35	Association of High Serum Interleukinâ€6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis and Rheumatology, 2020, 72, 1456-1466.	5.6	30
36	Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Doubleâ€Blind, Phase <sc>II</sc> Trial. Arthritis and Rheumatology, 2020, 72, 1435-1446.	5.6	83

#	ARTICLE	IF	CITATIONS
37	Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. <i>Rheumatology</i> , 2020, 59, 3834-3844.	1.9	45
38	Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. <i>RMD Open</i> , 2020, 6, e001490.	3.8	17
39	Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. <i>Rheumatology and Therapy</i> , 2019, 6, 503-520.	2.3	12
40	Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1788-1800.	5.6	284
41	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 315.	7.4	210
42	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1454-1462.	0.9	115
43	086 Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2019, 58, .	1.9	0
44	MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 887-895.	2.0	7
45	Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 3.	1.6	18
46	Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. <i>RMD Open</i> , 2019, 5, e001017.	3.8	9
47	FRI0075 SYSTEMATIC ANALYSIS OF INJECTION-SITE PAIN CAUSED BY SUBCUTANEOUS ADMINISTRATION OF THE ADALIMUMAB BIOSIMILAR FKB327 VERSUS ADMINISTRATION OF THE ADALIMUMAB REFERENCE PRODUCT VIA DIFFERENT DELIVERY METHODS. , 2019, , .		1
48	THU0173 FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) BY RACE & GEOGRAPHIC REGION. , 2019, , .		0
49	THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. , 2019, , .		5
50	SAT0132 LONG-TERM SAFETY, IMMUNOGENICITY AND EFFICACY IN RANDOMIZED, DOUBLE-BLIND, AND OPEN-LABEL EXTENSION STUDIES COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. , 2019, , .		0
51	FRI0092 SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). , 2019, , .		0
52	FRI0154 SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). , 2019, , .		2
53	AB0448 SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS. , 2019, , .		0
54	OP0029 SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
55	SAT0121â€¦EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES. , 2019, , .		2
56	LB0009â€¦ FIRST-IN-HUMAN STUDY OF NOVEL IMPLANTED VAGUS NERVE STIMULATION DEVICE TO TREAT RHEUMATOID ARTHRITIS. , 2019, , .		2
57	Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open, 2019, 5, e000887.	3.8	27
58	FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Research and Therapy, 2019, 21, 281.	3.5	34
59	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. Journal of Rheumatology, 2019, 46, 7-18.	2.0	207
60	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Annals of the Rheumatic Diseases, 2019, 78, 171-178.	0.9	66
61	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. Journal of Rheumatology, 2018, 45, 1085-1092.	2.0	28
62	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin Î² Receptor Fusion Protein, in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 1470-1480.	5.6	56
63	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology, 2018, 57, 900-908.	1.9	47
64	Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD Open, 2018, 4, e000581.	3.8	11
65	Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 14-21.	2.0	57
66	214â€¦Efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of a phase III monotherapy trial in patients with active rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	0
67	233â€¦Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. Rheumatology, 2018, 57, .	1.9	0
68	219â€¦Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities. Rheumatology, 2018, 57, .	1.9	1
69	Phase <sc>II</sc> Study of <sc>ABT</sc>â€¦122, a Tumor Necrosis Factorâ€¦ and Interleukinâ€¦17Aâ€¦Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2018, 70, 1778-1789.	5.6	77
70	<sc>ABT</sc>â€¦122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukinâ€¦17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2018, 70, 1710-1720.	5.6	55
71	217â€¦Improvements in remission and low disease activity are achieved with ongoing sarilumab treatment, in patients with rheumatoid arthritis in two phase III studies. Rheumatology, 2018, 57, .	1.9	0
72	Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology, 2018, 57, 2001-2011.	1.9	34

#	ARTICLE	IF	CITATIONS
73	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. <i>Rheumatology</i> , 2018, 57, 1972-1981.	1.9	30
74	Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. <i>Arthritis Research and Therapy</i> , 2018, 20, 57.	3.5	42
75	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. <i>Rheumatology</i> , 2018, 57, 1423-1431.	1.9	31
76	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet</i> , The, 2018, 391, 2513-2524.	13.7	316
77	Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017, 56, kew370.	1.9	42
78	Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 932-942.	5.6	78
79	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.9	83
80	Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1078-1085.	0.9	76
81	Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 414-417.	0.9	94
82	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1679-1687.	0.9	138
83	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1751-1761.	5.6	65
84	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet</i> , The, 2017, 389, 2317-2327.	13.7	316
85	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 943-952.	5.6	42
86	Secukinumab in Active Rheumatoid Arthritis after Anti-TNF $\pm$ Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. <i>Rheumatology and Therapy</i> , 2017, 4, 475-488.	2.3	25
87	OO3. CLINICAL AND RADIOGRAPHIC OUTCOMES AFTER 3 YEARS OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	1.9	0
88	Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 145.	3.5	12
89	Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1979-1983.	0.9	45
90	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	27.0	499



#	ARTICLE	IF	CITATIONS
91	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	3.4	43
92	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. <i>Arthritis Research and Therapy</i> , 2016, 18, 198.	3.5	56
93	VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 46-55.	5.6	110
94	Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2016, 68, 2857-2866.	5.6	172
95	Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naïve and TNF-IR Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 289-297.	2.0	28
96	Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. <i>Journal of Rheumatology</i> , 2016, 43, 298-306.	2.0	37
97	Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 343-349.	2.0	17
98	Increased pretreatment serum IFN- $\gamma$ /IL-10 ratio predicts non-response to tumour necrosis factor $\alpha$ inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.9	59
99	Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 49-55.	1.9	40
100	Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 430-42.	0.8	23
101	Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 80.	3.5	20
102	Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 159.	3.5	104
103	Dr. Genovese comments. <i>Journal of Rheumatology</i> , 2015, 42, 1994-1994.	2.0	0
104	Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 231-238.	0.9	8
105	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1424-1437.	5.6	213
106	Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy. <i>Arthritis Research and Therapy</i> , 2015, 17, 127.	3.5	53
107	Safety and efficacy of baricitinib at 24-weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 333-340.	0.9	232
108	Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. <i>Journal of Rheumatology</i> , 2015, 42, 1752-1760.	2.0	60

#	ARTICLE	IF	CITATIONS
109	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2123-2129.	0.9	39
110	Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1703-1710.	5.6	25
111	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1607-1615.	0.9	125
112	A1.72...Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study<sup>1</sup>. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A31.2-A31.	0.9	8
113	Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial. <i>Journal of Rheumatology</i> , 2014, 41, 629-639.	2.0	33
114	Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 3255-3264.	5.6	96
115	One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. <i>Journal of Rheumatology</i> , 2014, 41, 414-421.	2.0	88
116	A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naïve to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2014, 66, 1693-1704.	5.6	188
117	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-1 Antagonist. <i>Journal of Rheumatology</i> , 2014, 41, 2120-2128.	2.0	57
118	Serum 14-3-3 is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113.	2.0	72
119	Sarilumab, a fully human monoclonal antibody against IL-6 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1626-1634.	0.9	173
120	Long-term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment. <i>Arthritis and Rheumatology</i> , 2014, 66, 1987-1997.	5.6	48
121	Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2014, 370, 2295-2306.	27.0	350
122	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	3.9	381
123	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	2.0	108
124	Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-arm, Open-label Study. <i>Arthritis Care and Research</i> , 2013, 65, 718-728.	3.4	65
125	A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1453-1460.	0.9	47
126	Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1461-1468.	0.9	66



#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 863-869.	0.9	263
128	Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study. <i>Arthritis Care and Research</i> , 2013, 65, 362-371.	3.4	56
129	Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study. <i>Journal of Rheumatology</i> , 2012, 39, 1185-1191.	2.0	38
130	Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. <i>Journal of Rheumatology</i> , 2012, 39, 1546-1554.	2.0	61
131	Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 2012, 64, 617-629.	6.7	339
132	IL-17 receptor and its functional significance in psoriatic arthritis. <i>Molecular and Cellular Biochemistry</i> , 2012, 359, 419-429.	3.1	171
133	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 373-382.	3.4	58
134	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 846-854.	2.0	108
135	An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. <i>Arthritis and Rheumatism</i> , 2011, 63, 337-345.	6.7	190
136	Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , 2011, 63, 939-948.	6.7	264
137	Edward D. Harris, Jr., MD, 1937-2010. <i>Arthritis and Rheumatism</i> , 2010, 62, 2623-2624.	6.7	0
138	Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1158-1161.	0.9	115
139	Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1129-1135.	0.9	135
140	An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2010, 363, 1303-1312.	27.0	369
141	First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy. <i>Journal of Rheumatology</i> , 2009, 36, 1559-1559.	2.0	38
142	Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1429-1441.	2.0	89
143	Inhibition of p38: Has the fat lady sung?. <i>Arthritis and Rheumatism</i> , 2009, 60, 317-320.	6.7	182
144	Treatment of Rheumatoid Arthritis. , 2009, , 1119-1143.		7

#	ARTICLE	IF	CITATIONS
145	Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2652-2661.	6.7	193
146	Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2968-2980.	6.7	752
147	Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. <i>Journal of Rheumatology</i> , 2007, 34, 1040-50.	2.0	135
148	Long-Term Experience with Etanercept in the Treatment of Rheumatoid Arthritis in Elderly and Younger Patients. <i>Drugs and Aging</i> , 2006, 23, 167-178.	2.7	36
149	Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. <i>Arthritis and Rheumatism</i> , 2006, 54, 2793-2806.	6.7	1,462
150	Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. <i>Journal of Clinical Investigation</i> , 2006, 116, 2633-2642.	8.2	194
151	Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2005, 11, S45-S54.	0.9	30
152	Antigen microarray profiling of autoantibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2645-2655.	6.7	256
153	Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2005, 7, 407-415.	4.7	6
154	Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor $\gamma$ Inhibition. <i>New England Journal of Medicine</i> , 2005, 353, 1114-1123.	27.0	1,157
155	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1232-42.	2.0	89
156	A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. <i>Journal of Rheumatology</i> , 2005, 32, 2345-50.	2.0	3
157	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 1412-1419.	6.7	478
158	Treatment of rheumatoid arthritis with etanercept. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 311-328.	1.9	25
159	A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. <i>Arthritis Research</i> , 2004, 6, R73.	2.0	22
160	Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1014-1018.	6.7	10
161	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002, 46, 1443-1450.	6.7	664
162	Treatment of rheumatoid arthritis with total lymphoid irradiation: Long-term survival. <i>Arthritis and Rheumatism</i> , 2001, 44, 1525-1528.	6.7	4

#	ARTICLE	IF	CITATIONS
163	Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonist: By what mechanisms could tumor necrosis factor ? antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis and Rheumatism, 2001, 44, 1977-1983.	6.7	296
164	Lymphocyte Cc Chemokine Receptor 9 and Epithelial Thymus-Expressed Chemokine (Teck) Expression Distinguish the Small Intestinal Immune Compartment. Journal of Experimental Medicine, 2000, 192, 761-768.	8.5	607
165	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. New England Journal of Medicine, 2000, 343, 1586-1593.	27.0	1,776
166	Joint and soft-tissue injection. Postgraduate Medicine, 1998, 103, 125-134.	2.0	31
167	Immunogenicity of Subcutaneous and Intravenous Tocilizumab as Monotherapy or in Combination with Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis. Rheumatology, 0, , .	1.9	0